Registration is now open for the first ZH3D Academy course series on preclinical drug development.

This three-part course provides practical and regulatory insights into nonclinical drug development, with a focus on early stages and first-in-human enabling studies.

Course dates

Day 1 | Thursday, 15 October 2026 | On-site (University of Zurich, Centre) | 13:00–16:45

Day 2 | Thursday, 22 October 2026 | Online | 13:00–17:30

Day 3 | Thursday, 29 October 2026 | On-site (University of Zurich, Centre) | 13:00–16:45

Course format

• Three-part course series
• Participation is only possible for the complete course package
• Language: English
• Limited to 25 participants
• Course fee:
  External Participants: CHF 1’485
  UMZH Employees*: CHF 1’035
  UMZH Students*: CHF 735
  *Applicable to employees and students of UZH, ETH Zurich, USZ, University Children's Hospital Zurich, Balgrist and the University Hospital of Psychiatry Zurich.

Key topics

• Regulatory and quality aspects of nonclinical drug development
• Nonclinical drug development across different therapeutic modalities
• Nonclinical studies required for first-in-human clinical trial
• Practical guidance and how to avoid common pitfalls

Target group

PhD-Students, Postdocs, researchers from all disciplines, clinicians as well as start-up employees. Specific prior knowledge is not required.

Course lead

Dr. med. vet. Lisa Fischer, ERT

Head ZH3D Academy and Nonclinical Expert

Guest lecturers

Bärbel Ulmer, PhD, InSphero, Director Business Development

Dr.med.vet. Otto Maissen, BLV, Leiter Fachbereich Tierversuche

Registration

Register by 7 October 2026

zh3d.uzh.ch/en/academy-registration

Places will be allocated on a first come, first served basis.

A waiting list will be maintained once capacity is reached.